Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding 'Board Comments on fine levied by the Exchange '.
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
NSE and BSE had levied a fine on Akums Drugs and Pharmaceuticals for not following SEBI Listing Regulations 17(1) and 17(1A), which deal with the required composition of the Board of Directors. The company's Board met on August 8, 2025, to discuss this and stated that the delay was unintentional and a one-off issue caused by the late finalisation of a suitable independent director candidate. The company has since appointed an independent director, thereby fixing the non-compliance. A fine waiver application with supporting documents has already been submitted to NSE, and the Compliance Officer has attended a personal hearing; the NSE's decision on the waiver is still pending.
This is a minor governance compliance issue with a relatively small regulatory fine, and the company has already remedied it by appointing the required independent director. Shareholders should watch for NSE's waiver decision; the matter is unlikely to materially affect the stock price but reflects a lapse in board composition timelines.